Dr. Peters on Creating Algorithms for Personalized Therapy in NSCLC
Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.
Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.
In the past 3 to 5 years, the treatment paradigm of non—small cell lung cancer has completely changed, creating long-term survivor outcomes in metastatic disease and a number of novel treatment options, explains Peters. All patients should receive immunotherapy, ideally in the frontline setting, she explains.
There should be a heavier focus on precision oncology in NSCLC, including defining biomarkers for improved patient selection and understanding predictive factors to treatment. Creating algorithms for personalized immunotherapy will take some time, but Peters believes it is important in creating effective treatment. For sequencing, Peters recommends using single-agent or combination immunotherapy to treat patients with early-stage disease.
